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Abstract: Dupuytren disease (DD) is a common fibroproliferative disease of unknown 
  etiopathogenesis affecting the palmar aponeurosis, causing reduced hand function and resulting 
in fixed flexion contractures of the digits. Current gold standard treatment for the management 
of DD is surgical excision involving removal of the affected palmar fascial tissue. However, 
there are potential complications associated with surgery as it is costly and a positive surgical 
outcome is often short-lived because the disease tends to recur. Therefore, there is growing 
interest in nonsurgical, outpatient-based treatments that could be quicker, cheaper, reduce 
morbidity, show a decreased rate of recurrence, and give DD patients an improved quality of 
life when compared with traditional surgical management. Of the available nonsurgical options, 
injectable Clostridium histolyticum collagenase (CHC) has received recent clinical interest. 
In this article, a brief overview of DD surgical and nonsurgical treatments utilized is given, 
followed by a detailed examination of the nine papers published to date on the use of CHC in 
DD (and similar fibrotic disorders). These papers have investigated safe and efficacious doses 
for the injection of CHC to treat palpable DD cords in adult patients and have shown significant 
short- to mid-term results for correction to near-full digital extension (#5° extension) following 
CHC injection of DD cords. CHC has been shown to target the collagen-based DD cords while 
sparing surrounding neurovasculature, with a complication profile that appears comparable to 
that of the surgical methods currently utilized. In conclusion, clostridial collagenase is a novel 
nonsurgical treatment option of considerable potential in the management of DD when admin-
istered by specialist hand surgeons with detailed knowledge of the disease and the relevant 
anatomy. Nonetheless, there is a need for further data on long-term results, complications, and 
rate of recurrence with the use of this emerging treatment option.
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Introduction
Dupuytren disease (DD) is a common, fibroproliferative disease affecting the hands 
and resulting in fixed flexion contractures that are progressive and irreversible.1 This 
deformity results in considerable disability and can limit patient activities of daily 
living, manual activities, and sporting hobbies, markedly reducing patients’ quality of 
life.2 There are a variety of treatments that have been investigated, with the ongoing 
mainstay being surgical correction involving either release or excision of the affected 
palmar fascia. However, there has been an increasing interest in the use of and clinical 
success with the utilization of injectable Clostridium histolyticum collagenase (CHC) 
for the nonoperative treatment of DD.3–10 Recent clinical trials3,5,9,11–18 have shown 
encouraging results, to the extent that this novel technique will likely be used frequently Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in future clinical practice – hence, it is important to explore 
the efficacy and safety profile of such a technique.
The aims of this review are to give an overview of DD 
and its current treatment options, with particular focus on the 
nonsurgical methods trialed historically; to give a synopsis of 
the history and uses of CHCs to date; to summarize the uses 
of such CHCs within the field of DD (and associated fibrotic 
conditions); and, to highlight the growing utility of such col-
lagenases within the treatment options available for DD.
Methods
Searches were undertaken using Medline, PubMed, and Sco-
pus to identify seminal studies and reviews using all keywords 
relating to DD and CHC. To ensure no studies were missed, 
the references of each selected study or review were also 
searched and any relevant articles were included. All relevant 
European and US patents were reviewed, plus all US Food 
and Drugs Administration (FDA) documentation relating to 
the Xiaflex® (Auxilium Pharmaceuticals Inc., Malvern, PA) 
application for approval (granted in February 2010). Finally, 
the product specification sheets for the commercially available 
clostridial collagenases were reviewed.
DD – an overview
DD is a benign yet progressive, fibroproliferative disorder of 
unknown origin affecting the palmar fascia and extending into the 
digits of the hands.1 It is commonly bilateral, with a pathological 
transformation of the fascial tissues into thickened fibrous nodules 
and cords which, on progression to the advanced stage of the 
disease, result in irreversible flexion contractures of the involved 
digits.19 DD can be associated with extra-palmar ectopic fibrosis 
over the knuckle pads, known as Garrod nodes;20 in the sole of 
the foot, known as Lederhose disease or plantar fibromatosis;21 
formation of fibrotic plaques within the corpora cavernosal tunica 
albuginea, resulting in penile bending during erections, known as 
Peyronie disease (PD);22 and, uncommonly, with involvement of 
the wrist20 or with nodular fasciitis in the popliteal space.19
DD was first described in the medical literature in 1831 
by the eponymous Baron Guillaume Dupuytren,23 although 
Dupuytren was not the first to describe this disease. Henry 
Cline, in 1777, initially described DD as a palmar fascial 
disorder through his study of cadaveric specimens: he first 
noted the contribution of the palmar fascia to the disorder, 
then, 10 years later, suggested its treatment via palmar 
fasciotomy.23,24 In addition, Cline’s student, Sir Astley Cooper 
wrote in 1822 on this disease and demonstrated a procedure 
similar to needle fasciotomy.25 Dupuytren visited Cooper 
in 1826 but did not perform his first surgery (on his coach 
man) until 1831 – this was the operation he later described 
and published in Lancet.26
The prevalence of DD is thought to be affected by gender, 
age, ethnicity, and geographical origin.27 The male to female 
incidence ratio ranges between 5:1 and 15:1,28 although 
the frequency in women increases substantially with age, 
catching up to that seen in men in later life.29 Rarely, children 
as young as 9 years have been diagnosed with the condition.30 
More commonly, men tend to present in the fifth decade, 
whereas women require treatment later23 –   irrespectively, the 
incidence in both sexes increases with age, with the reported 
prevalence in northern Europe for men older than 65 years 
being between 18% and 30%.31 DD is primarily a disease 
of northern European caucasians, with only sporadic case 
reports of it affecting nonwhite individuals. Where nonwhite-
skinned populations are affected, eg, the Japanese (where 
the prevalence is similar to that seen in northern Europe) 
and, rarely, African Americans, authors have postulated a 
prior interracial mixing in the genetic lineage of the affected 
individuals.23 Geographically, DD is commonest in the 
United Kingdom, Scandinavia, North America, Australasia, 
and Japan, with a markedly decreased prevalence in the more 
southerly Mediterranean regions and South America. DD is 
considered to be rare in Africa and China.27,32
The etiology of DD remains controversial, with asso-
ciations of varying significance having been found with 
heredity,27,33,34 alcohol consumption,35 smoking,36 diabetes 
mellitus,37,38 epilepsy (or antiepileptic medications),39,40 raised 
serum lipids,41 local injury (leading to algodystrophy and dis-
use of the affected hand),42 and occupations involving vibra-
tion exposure.43 Of these, genetic heritability undoubtedly 
has a significant etiological contribution, with some authors 
suggesting a Mendelian autosomal dominant transmission 
with variable penetrance44 and others suggesting DD to be 
a complex trait (like diabetes, hypertension, or cancer).31 
The associations with smoking, diabetes, raised serum 
lipids, and alcohol consumption have been suggested to be 
related to the microangiopathic ischemia that underlies these 
  conditions – this results in increased free radical production, 
which stimulates fibroblast proliferation and cytokine release, 
potentially leading to the development of DD.45
The pathophysiology of DD is complex and multifactorial, 
to date eluding the establishment of an overarching pathophys-
iological model despite substantial investigative efforts. The 
disease affects the palmar fascial tissues,   causing abnormali-
ties in fibroblast proliferation,   myofibroblast   production, and 
collagen deposition that result in the development of the 
structurally distinct nodule and cord disease components.46 Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Three distinct histological phases have been described.23 The 
proliferative stage, the most biologically active phase of the 
disease, is characterized by local fascial fibroplasia and myo-
fibroblast proliferation resulting in nodule formation. Next 
follows the involutional stage in which the myofibroblasts 
become aligned along lines of tissue mechanical stress, 
demonstrating progressive contractile behavior triggered 
by the effect of a variety of cytokines on the intracellular 
actin   microfilaments – this results in the formation of the 
progressively shortening fascial cords. In the final disease 
stage, termed the residual phase, nodules regress leaving the 
tendon-like, inelastic, relatively acellular cords that cause the 
clinically apparent fixed flexion contractures.23 Normal palmar 
fascial tissue is primarily composed of type I   collagen – in DD, 
the increased density and decreased apoptosis of fibroblasts, 
plus an imbalance in matrix metalloproteinase activity, result 
in excessive type III collagen production.45
Irrespective of the underlying etiological factors, what 
primarily concerns patients is the degree of manual functional 
disability that DD imposes.47 Studies that objectively attempt 
to link severity of DD contractures and manual disability 
have shown little to no correlation between the severity of 
contracture and the degree of manual disability (as assessed 
by the disability of the arm, shoulder and hand [DASH] 
questionnaire).48 This may be unsurprising because the DASH 
is neither DD-specific nor hand-specific, with an emphasis 
on pain (not a cardinal feature of DD) – a DD-specific hand 
function questionnaire has yet to be validated. Also, there 
are no objective papers to date examining the impact of 
DD on patients’ quality of life. Nevertheless, the authors’ 
experience is that patients commonly complain of problems 
with shaking hands, putting on gloves, typing, performing 
recreational activities (eg, golf and gardening), and perform-
ing basic personal care activities (eg, washing their face).1 
Despite a lack of formal documentation of the impact of such 
problems, it is obvious that such activity impairment must 
affect patients’ quality of life and thus stimulate the drive to 
seek correction of the imposed deformities.
Management issues in DD
DD classically progresses in two distinct manners. In the less-
common disease form associated with the term diathesis and 
usually found in patients with a strong familial predisposition 
to the disease, the progression tends to be more aggressive 
with contractures developing over a few months to years and 
with rapid disease recurrence after surgical   interventions.49 
The more common disease form not associated with   diathesis, 
where there is no obvious familial preponderance, usually 
progresses more slowly, often allowing the patient to maintain 
sufficient hand function to live with the disease for years prior 
to seeking treatment, following which there is a lower risk 
of disease recurrence.49 To date, there is no known cure for 
either form of the disease, but its impact has been commonly 
managed with appropriate surgical intervention.
In view of the variability in the rate of disease progres-
sion and the extent of disability caused to patients’ hand 
function, initial treatment of DD usually involves watchful 
waiting to observe the rate of progression of the disease until 
the contractures are significantly affecting a patient’s hand 
function or their activities of daily living.1 Currently, the 
gold standard treatment in DD is surgical, with a choice of 
selective, segmental, limited, or modified fasciectomy; radi-
cal or total aponeurectomy; or dermofasciectomy to excise 
the affected fascial tissue and restore digital extension1 (the 
operation is chosen at the surgeon’s discretion and depending 
on the extent of the disease – dermofasciectomy is most com-
monly used in recurrent cases, particularly those involving the 
proximal interphalangeal joint [PIPJ]). Other less-invasive 
surgical treatment options include closed fasciotomy and 
needle aponeurotomy, both of which incise the fascial bands, 
causing rupture of the cord.50–52 These methods are much less 
invasive and can achieve digital extension, but they have been 
associated with higher rates of recurrence, generally being 
reserved for elderly or infirm patients in whom the risks of 
more extensive surgery outweigh the improved recurrence 
rate benefit.53 Overall, the development of a nonsurgical 
treatment option for this disease may improve morbidity and 
recovery time and enhance patients’ quality of life.
To date, a variety of nonsurgical treatments have been 
investigated with variable success. These have included the 
administration of steroids,54,55 dimethyl sulfoxide,56 vitamin E 
(tocopherol),57 radiotherapy,58–60 ultrasonic therapy,61 physical 
therapy,47 methylhydrazine,62 allopurinol,63 enzymatic fas-
ciotomy (using a combination of trypsin, hyaluronidase, and 
lidocaine),64 and collagenase3,5,9,11–18 (see Table 1). Steroid 
injection of the nodules has shown some clinical promise in 
modifying the disease progression (97% of nodules injected 
showed some softening or flattening; however, 50% of these 
patients exhibited recurrence within less than 3 years)54 and 
merits further investigation. However, to date, the most clini-
cally promising of these treatments has been the use of inject-
able CHC to locally degrade the collagen structures, allowing 
rupture of the fibrous cords and restoration of   complete or near-
complete digital extension (see CHCs and fibrotic disease).
In view of the emergence of, and potential for, increasing 
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Table 1 All papers retrieved relating to CHC use in the management of fibrotic disorders, in their chronological order of publication
Authors/refs Disorder Aim/end point Key findings
Gelbard11 PD effect of CHC on: healthy vs PD-affected 
tunica albuginea surrounding tissues 
following injection into rat femoral canal
No significant difference in the degree of collagen degradation 
between the diseased and healthy tissues 
visible tissue clearing within the injection zone but not outside  
the radius of the zone 
Collagenolysis with preservation of elastin and no evidence of 
injury to local neurovasculature 
Macroscopic hematoma; microscopic venule and perineurium 
degradation with sparing of arterioles and endoneurium
Starkweather12 DD effect of injected CHC on tensile 
strength of DD cords
Phase i: 3,600 U injection; 10 CHC vs 10 control injections; 
93% decrease in tensile modulus 
Phase ii: dose response (150/300/600 U/control); curvilinear trend 
between increased dose and decreased tensile strength
Badalamente13 DD in vivo effect of CHC on joint 
contractures – correction to #5° 
extension
Phase i: dose trial (300, 600, 1,200, 4,800, 9,600 U) – no cord 
rupture 
Phase ii: 10,000 U; 29 patients – 88% correction of MCPJ, 44% full 
correction of PiPJ; 2 MCPJ, 2 PiPJ no response – surgery required; 
No major adverse reactions, no clinical systemic immune 
response
Badalamente14 DD in vivo effect of CHC on joint 
contractures – correction to #5° 
extension (PCRT)
Phase i: 
MCPJ – 14/18 CHC-injected joints achieved primary end point vs 
2/18 placebo; 4/18 recurrence at 4 y 
PiPJ – 5/7 CHC-injected joints achieved primary end point vs  0/7 
placebo; 4/7 recurrence at 4 y
Phase II: dose-response (2,500, 5,000, 10,000, placebo): significantly 
dose related, 10,000 U most effective; 90% MCPJ and 70% PiPJ 
achieved primary end point; 1 MCPJ and 1 PiPJ of 80 patients 
showed recurrence at 2 y 
Substudy 1: pharmacokinetics of CHC – no CHC in serum; 28% of 
administered CHC dose found in urine 1 h after CHC injection in 
DD cord 
Substudy 2: addition of lidocaine for joint manipulation in 
5 patients; well tolerated and no effect on end point
Kang16 Keloid effects of CHC/triamcinolone/
combination of both on scar
Mixed keloid and hypertrophic scars (7 patients): keloid – 
33% reduction in scar volume in first 6 mo, then effect lost; 
hypertrophic scars – no effect 
Patient-perceived severe reactions to treatment
Badalamente9 DD in vivo effect of CHC on joint 
contractures – correction to #5° 
extension (PCRT)
Blinded PCRT: 55 joints; 10,000 U/injection; multiple injections to 
achieve primary end point; 91% CHC joints achieved primary end 
point vs 0% placebo 
Open phase: 35 joints, given CHC injection; 77% achieved primary 
end point; 5/35 showed disease recurrence at 2 y
Del Carlo17 PD and 
DD
in vitro effect of CHC when injected 
into PD plaques and DD cords
enzymatic effect maximal at 4 h; near-complete digestion at 12 h; 
no cellular death; noncollagenous tissues unaffected
Hurst5 DD in vivo effect of CHC on joint 
contractures – correction to #5° 
extension (PCRT)
512 joints: 64% CHC joints achieved primary end point vs 6.8% 
placebo joints 
96.6% CHC joints developed $1 treatment-related adverse event 
vs 21.2% placebo joints 
3 patients with severe CHC-related adverse events: 1 complex 
regional pain syndrome; 2 tendon ruptures 
Biochemical immune response in $85.8% of patients with 1 CHC 
injection and 100% with 3 CHC injections; no clinically apparent 
systemic immune responses
watt3 DD Recurrence rate 8 y after single CHC 
injection – correction to #5° extension
MCPJ – 2/6 no recurrence; 4/6 recurrence 
PiPJ – 2/2 recurrence 
Patient perceived subjective success of treatment – 60% successful; 
7/8 would consider repeat treatment
Abbreviations: CHC, Clostridium histolyticum collagenase; PD, Peyronie disease; DD, Dupuytren disease; MCPJ, metacarpophalangeal joint; PiPJ, proximal interphalangeal 
joint; PCRT, placebo-controlled, randomized trial.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the development, mode of action, pharmacokinetics, and 
current uses of the commercially available collagenases and 
details the issues related to its application in the nonsurgical 
  treatment of DD.
Collagenase C. histolyticum
The history of the proteolytic enzymes derived from Clostrid-
ium bacterial species dates back to the early 20th century 
when it was observed that culture filtrates from Clostridium 
perfringens had the ability to digest healthy muscle   tissue.65 
However, it was not until the 1940s when the ability of such 
culture filtrates to break down the collagen framework of 
healthy Achilles tendon was observed, that this novel enzyme 
was named collagenase.65 Since then, an increasing number of 
bacterial species, often those that are pathogenic in humans, 
have been shown to produce collagenases, which contribute 
to their pathogenicity.66 Collagen, which comprises nearly 
30% of all proteins within mammalian bodies, is an insoluble 
structural matrix protein composed of three helically wound 
polypeptide fibrils – it is resistant to degradation by the major-
ity of proteases due to its triple helical structure which requires 
unwinding before proteolytic degradation can occur.66,67 
Degradation is key to a variety of both physiological 
(eg, embryological bone development and wound repair) 
and pathological conditions (eg, tumor invasiveness and soft 
tissue bacterial infection), so the human body also produces 
its own endogenous collagenase as part of the family of zinc-
dependent matrix metalloproteineases.68
To date, CHCs have been investigated for clinical use in 
the treatment of herniated intervertebral discs,69–71 retained 
placenta,72 frozen shoulder adhesive capsulitis,73 DD (see 
section “CHC and fibrotic disease”), PD,11,17,74 wound heal-
ing,75–77 in the debridement of burns,76,77 and in the preparation 
of pancreatic islet cells for transplantation.16,78 It has also been 
suggested that CHC could be used in the treatment of keloid 
scars,16 for recannalization of chronically occluded arterial 
vessels or stents within peripheral arterial angioplasty pro-
cedures79 and in the amelioration of plantar fasciitis,7 lateral 
epicondylitis,7 and cellulite removal.10 This review focuses 
on the uses of clostridial collagenases in the treatment of 
fibrotic disorders, with the primary focus on its use in the 
nonsurgical management of DD.
Pharmacology
Seven collagenases have been isolated from the culture 
filtrate of the bacteria C. histolyticum, namely α, β, γ, δ, ε, 
ξ, and η collagenases.80 They are all zinc-dependent matrix 
  metalloproteinases whose unique specificity is in the   hydrolysis 
of collagen molecules via the peptide bond between the Gly-Pro 
and residue X of the tri-peptide repeat unit (where residue X 
is often proline or hydroxyproline).68 The seven collagenases 
can be divided into two classes, I and II, which are classified 
based on their bacterial gene of origin (colG and ColH, respec-
tively) and on their point of hydrolytic attack on the collagen 
molecule – class I enzymes act at loci near the ends of the 
collagen triple-helical domains, whereas class II enzymes make 
internal initial cleavages80–82 (see Figure 1) – their combined 
action at many sites along the peptide chain results in the 
sequential cleavage of short segments. Both classes have spe-
cific binding domains that enable them to recognize and bind to 
triple helical collagen.83,84 The biochemical properties of CHCs 
mark them out as potentially useful targets for in vivo clinical 
applications: these include their ability to remain active over 
a wide pH range (the optimum being pH 7.4); a high degree 
of substrate specificity, with degradation of only the collagen 
components of connective tissue structures; a good enzymatic 
activity at body temperature (37°C); a lack of autodigestion; 
and, that they can be lyophilized safely and then reconstituted 
directly prior to use allowing for easy storage and a good 
stability profile.11 With regard to inhibitors of CHC activity, 
CHCs are dependent on the presence of Ca2+ ions and, thus, 
must be diluted in buffer solution containing Ca2+ prior to their 
utilization – interestingly, a dose-dependent, predominantly 
noncompetitive inhibition of CHC activity has been noted with 
the aloin compounds contained within the mucilaginous sap of 
the Aloe barbadensis plant, commonly referred to as Aloe vera 
gel (however, this is via direct interaction with the collagenase 
molecule and not via its catalytic domain).85
CHCs are manufactured via bacterial fermentation, 
following which the different collagenases can be separated 
off chromatographically – the majority of commercially avail-
able CHCs are produced in this manner. However, a drawback 
of this method is that the ratio and activity of class I and 
class II CHCs yielded is unreliable, so each CHC batch can 
have differing biological effects.7 There are a large variety of 
commercially available CHC preparations, each with differing 
selectivity of included CHCs, and this allows for the different 
uses to which CHCs are put in the laboratory setting. For in 
vivo human clinical trials, the investigators have been care-
ful to select highly purified preparations in order to maintain 
maximal reproducibility. However, more recent work has 
utilized a novel CHC, designed specifically for medical thera-
peutic applications and marketed as   Xiaflex®, which gained 
US FDA approval on February 2, 2010 and is expected to 
achieve European approval in January 2011. This bypasses 
the issues of unreliable interbatch reproducibility by highly Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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purifying the initial culture filtrate to select a 1:1 mass ratio of 
class I to class II CHCs, thereby guaranteeing a reproducible 
collagenolytic effect.7
CHCs and fibrotic disease
A timeline of key events in the development of CHC use in 
DD is illustrated in Figure 2. Literature searches retrieved 
all papers relating to CHC use in the management of fibrotic 
disease (ie, DD, PD, and keloid scarring), and these are listed 
for ease of reference in Table 1 and discussed in chronologi-
cal order of publication hereafter.
The initial pilot study in the examined series was a mul-
tifaceted pilot by Gelbard et al11 who looked at the in vitro 
collagenolytic effect of commercially available CHC on 
human PD tissue, healthy tunica albuginea, pericardium, and 
corpora cavernosal sections, plus the in vivo effect of CHC 
on the femoral neurovascular bundle of an anesthetized rat. 
First, they compared CHC activity (via measurement of desic-
cated tissue weight and release of free α-amino acid groups) 
on PD plaque tissue and healthy tunica albuginea tissue, with 
tissue derived from three patients for each tissue type. They 
showed there was no significant difference in the degree of 
collagen degradation between the diseased and healthy tissues,   
ie, CHC did not selectively degrade PD plaque collagen but 
would affect surrounding healthy tissues. To look into the effect 
of local injection of CHC and dispersion into surrounding 
tissues they investigated injecting CHC at a variety of unit 
strengths into human pericardium and demonstrated that when 
CHC was injected locally into tissue, there was a dose-related 
response, but this was always limited to the injection site – with 
a dose of 400 U, there was visible tissue clearing within the 
injection zone but not outside the radius of the zone. They 
suggested this confinement of digestion to be related to the 
mucopolysaccharide “ground substance” in which the collagen 
is embedded and which does not undergo digestion itself. Next, 
they injected 400 U into sections of PD-affected and healthy 
corpora cavernosa – this caused collagenolysis (varying on 
histological examination from decreased stain uptake to total 
disappearance of collagen bundles) but with preservation of 
elastin and with no evidence of injury to the local neurovas-
culature. Finally, they injected 600 U of CHC into the adven-
titia surrounding the left femoral neurovascular bundle of an 
anesthetized rat – 24 hours later, the rat was sacrificed, and 
the treated and untreated femoral neurovascular bundles were 
Class I
AUX-I
Class II
AUX-II
Class II
AUX-II
Preferentially cleaves
fragments from central
collagenous domain
N-terminal
Triple-helical collagen domain
C-terminal
Preferentially cleaves
end-portions of intact
collagen molecules
Class I
AUX-I
Figure 1 illustration of classes of Clostridium histolyticum collagenase (CHC) based on their hydrolytic point of attack on collagen molecule: class i CHCs act at loci near the 
N and C terminals of the collagen domain; class ii CHCs cleave within the central collagen domain – the combined action of both classes synergistically effects thorough 
degradation of the collagen triple helix.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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compared. Macroscopically, a moderate hematoma was noted 
with no signs of active   bleeding. Microscopically, venules and 
the fibrous perineurium underwent degradation, but there was 
no effect on arterioles or the nerve fibers themselves – this was 
postulated to be due to the smooth muscle in the arteriolar walls 
and the myelin sheaths enveloping and thus protecting the 
nerves. Based on Garvin’s experiments82 on the cytotoxicity of 
intravenous CHC in rats (see Discussion for greater detail), the 
authors extrapolated that the cytotoxic dose in a 70 kg human 
might be around 89,040 U, which was 356 times more potent 
than the doses they had found to be required for adequate 
collagenolysis at a local injection level.
In the first of a number of papers submitted by the same 
US-based group of investigators, Starkweather et al12 ana-
lyzed the effect of injected CHC on the tensile strength of DD 
cords obtained from patients who had undergone fasciectomy. 
All cords were subjected to controlled stretching within a 
mechanical testing device that recorded stress and strain 
effects within the cords, following which they underwent 
histological examination. In the first phase of the study, 
the authors compared the effect of 3,600 U CHC injections 
in 10 DD cord samples against 10 cords injected with a 
control buffer solution. Cords injected with CHC showed 
a statistically significant 93% decrease in tensile modulus 
when compared with the control buffer-injected cords. In 
the second phase of the study, 20 DD cord samples were 
randomly allocated into groups and subjected to an injection 
of 150, 300, or 600 U of CHC or a control buffer solution. 
Each cord was stressed to failure, ie, until cord rupture 
was achieved, with a curvilinear trend being demonstrated 
between increasing CHC dose and decreasing stress required 
to achieve cord rupture – 89% of the trend was directly 
attributable (following regression analysis) to the CHC dose 
administered. The stress to failure values were then compared 
with the average stress normally generated by the active 
extension of each of the fingers in a healthy hand. This 
allowed extrapolation that a CHC injection of 300 U was the 
minimum potential dose for in vivo clinical use that would 
result in DD cord rupture (and hence correction of the fixed 
flexion deformity) following normal active digital extension. 
One point to note was that the authors believed that it was 
important to inject CHC into DD cords (these being in the 
residual disease stage and relatively acellular when compared 
with the more active nodular areas of disease) as it was sug-
gested this might minimize early recurrence or the risk of 
worsening the flexion contractures.
Investigation of the utility of CHC in the treatment of 
DD was next progressed by Badalamente and Hurst13 who 
assessed the in vivo efficacy and, importantly, safety of CHC 
injection within a 32-patient Phase II open-label trial. The 
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study end point was correction of metacarpophalangeal joint 
(MCPJ) or PIPJ fixed flexion contractures to full extension 
(0°–5°) and assessment of any related adverse reactions 
(see Figure 3 for an illustration of the anatomical landmarks 
associated with CHC in vivo injections). The immunological 
effect of CHC injection was also assessed via serial serum 
immunoglobulin E (IgE) assays at days 1 and 14 postinjection. 
Follow-up was maintained between 2 and 5 years postproce-
dure to assess disease recurrence. Based on the prior in vitro 
determination of 300 U being a safe and effective CHC dose 
for cord rupture, the first patient was given an injection of 
300 U – this failed to achieve cord rupture. The dose was 
then escalated, with trials of 600, 1,200, 4,800, and 9,600 U 
each in a single patient – again cord rupture was not achieved. 
The remaining 29 patients (ie, 34 MCPJ, 9 PIPJ, and 1 
thumb joint contractures) had 10,000 U CHC injected into 
each contracture-contributing DD cord with passive digital 
extension 24 hours later to effect cord rupture. Following 
rupture, participants were asked to undertake patient-guided 
extension exercises and application of night extension splints 
for 4 months following the procedure to maintain maximal 
digital extension. Within 2 weeks of the procedures (some 
of which required repeat injections to achieve cord rupture), 
an 88% success rate was noted in the correction of MCPJ 
contractures and a 44% success rate in PIPJ contracture 
correction (to 0°–5° of extension). Two patients with MCPJ 
disease and 2 with PIPJ involvement failed to achieve cord 
rupture and digital extension so required surgical correction 
via fasciectomy. There were no major adverse reactions, but 
there were transient (1–2 week) minor reactions local to the 
injection site, including tenderness, palmar and/or dorsal 
edema, small local hematoma formation, forearm tenderness, 
and elbow/axilla lymphadenopathy. Three MCPJ contractures 
relapsed at 2-year postprocedure follow-up along with one 
PIPJ recurrence 3 months following treatment. Finally, IgE 
titers were seen to increase, especially in patients requir-
ing repeat treatments; however, they were not associated 
with any adverse clinical effects and decreased with time 
postprocedure.
This work was followed in 2002 by another Phase II 
trial undertaken by the same group of authors, Badalamente 
et al.14 The first trial leg was a single-center, randomized, 
placebo-controlled, double-blinded trial comparing the effect 
of injection of 10,000 U of CHC against placebo in patients 
with MCPJ or PIPJ DD-related contractures. 36 MCPJ and 
13 PIPJ contracture patients were recruited and split equally 
between the treatment and placebo groups. Again, the primary 
end point of the study was correction of MCPJ or PIPJ fixed 
flexion contractures to full extension (0°–5°), the secondary 
end point was the percentage change from the preinjection 
baseline of range of motion and grip strength, and the final goal 
was identification of any related adverse reactions. In patients 
with multidigit involvement, the injections were repeated as 
required up to a maximum of 50,000 U. In the MCPJ group, 
there was a statistically significant difference between the 
treatment and placebo groups with 14 of 18 treated patients 
achieving the primary end point within 2 weeks, compared 
with two of 18 placebo patients. Within the 4-year follow-up 
period, four treated patients had disease recurrence. In the 
PIPJ group, five of seven treated patients achieved the primary 
end point within 4 weeks, compared with none of six placebo 
patients. Within the 3.8-year follow-up period, four treated 
patients had disease recurrence. Range of motion and grip 
strength showed no significant decline from baseline in either 
group. Adverse effects of CHC injection were the same as 
detailed in the authors’ previous paper, remaining locally con-
fined and well tolerated, with the addition of three superficial 
skin tears secondary to rapid stretching of the overlying skin 
during cord rupture. The next study leg was a dual-center, 
DD cord
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interphalangeal joint
Metacarpophalangeal
joint
DD cord
Deep fat/
connective tissue
Flexor tendon
Metacarpal bone
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Figure 3 Diagram illustrating: A) hand with palpable “bow-stringed” Dupuytren 
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randomized, placebo-controlled, double-blinded trial inves-
tigating the optimum dose of CHC required and involving 
80 patients, evenly randomized to placebo, 2,500, 5,000, or 
10,000 U doses. The end points were identical to the first trial 
leg. The success rate in restoration of full extension at 1-month 
postprocedure was significantly dose related, with MCPJ joints 
injected with 10,000 U showing a 90% success rate and PIPJ 
joints 70% success. Flexion and grip strength showed no sig-
nificant deviation from the baseline and adverse effects were 
similar to those shown in the first trial leg. One MCPJ and one 
PIPJ had a disease recurrence within the follow-up period of 
2 years. Finally, there were two substudies undertaken. The 
first investigated CHC pharmacokinetics – four participants 
given the 10,000 U CHC treatment had serial blood and 
urine samples taken over an 180-minute period and 24-hours 
postinjection for analysis of their collagenase content. There 
was no collagenase detected within the serum (likely due to 
its slow release into the bloodstream); however, levels were 
detectable in the urine primarily in the first hour postinjection, 
with up to 28% of the administered dose recovered from the 
urine. The second substudy examined five patients receiving 
10,000 U but who had lidocaine injected prior to the passive 
digital manipulation to cause cord rupture 24 hours postin-
jection. This was well tolerated and demonstrated no effect 
on the study end points. Overall, the authors concluded CHC 
injection to be safe, effective, and less-invasive treatment 
option for the management of DD contractures.
Following these impressive results, the use of CHC in the 
treatment of keloid and hypertrophic scarring was piloted by 
Kang et al.16 They injected CHC, triamcinolone, or a combi-
nation into the keloid or hypertrophic scars of seven patients, 
and the response was measured by scar volume studies, visual 
subjective evaluation of response, serial photographs, and 
diarized patient experiences. A 33% reduction in propor-
tional keloid scar volume was noted in the first 6 months 
with collagenase, but this effect disappeared thereafter. CHC 
produced no alteration in volume in the injected hypertrophic 
scars. CHC injection was associated with moderate local pain, 
severe blistering, skin ulceration, bruising, and swelling – 
one participant had severe enough symptoms to necessitate 
hospital admission for antipyretics and supportive measures. 
Overall, the authors concluded that intralesional injection of 
collagenase is ineffective and, coupled with the possibility of 
serious adverse reactions, has little scope as a clinical treat-
ment for keloid or hypertrophic scars. However, it must be 
noted that the study sample size was not large enough, nor 
the scar group selected of a sufficient homogeneity, to draw 
any strong conclusions for or against the technique.
Returning to the previously discussed US group, the next 
article by Badalamente and Hurst9 continues on from their 
earlier studies with a Phase III randomized, placebo-controlled, 
double-blinded trial followed by an open-label extension. 
A total of 55 DD-contracted digits requiring treatment were 
recruited for injection with 10,000 U of a novel, mixed subtype 
CHC preparation. Within the main trial, patients had up to 
three joints injected, with a maximum of three injections into 
the primary joint followed by up to two in any remaining joints. 
A further three injections were allowed in the extension study 
if required. The primary end point was overall clinical success 
ie, reduction in deformity to #5° within 30 days of primary 
joint injection(s) – again, adverse reactions were recorded. 
Within the blinded phase, 91% of CHC-treated joints (86% 
of MCPJ and 100% of PIPJ joints) vs 0% of placebo group 
achieved clinical success (with up to three injections given 
and a mean number of injections to success of 1.4). 35 joints 
were entered into the open phase, where all were treated with 
CHC – 77% achieved clinical   success. Over the 2-year follow-
up period, one MCPJ and four PIPJ joints exhibited a disease 
recurrence – of these, the four male patients had a family his-
tory of DD, but the single female patient had de novo disease. 
Adverse events were of the same nature as detailed in the 
earlier Badalamente et al studies, with no summative systemic 
enzymatic effect or change in event severity demonstrated 
with repeated   injections. There were no adverse immune   
events.
Xiaflex® was then utilized in a study by Del Carlo 
et al17 examining its in vitro effect when PD plaques and 
DD cords were injected with increasing concentrations of 
the CHC. Maximal enzymatic activity occurred within the 
first 4 hours, and near-complete digestion of the samples 
occurred following 12 hours of CHC   exposure – small fibrils 
were preferentially degraded in the first 4 hours, following 
which the degradation of the larger fibrils proceeded. No 
cell death was observed at any concentration of CHC and 
all noncollagenous tissue structures remained histologically   
intact.
The two most recent CHC papers published originated 
from members of the same US-based group. The first, by Hurst 
et al5 (who make up the Collagenase Option for Reduction of 
Dupuytren’s [CORD] I study group) expands on the earlier Phase 
III study by Badalamente and Hurst. However, this 90-day Phase 
III prospective, randomized, placebo-controlled, double-blinded 
trial extended across 16 centers and had a substantially larger 
patient sample group (of 308 participants or 512 DD-affected 
joints) than previous studies. DD cords were injected with 
0.58 mg of CHC (Xiaflex®) – a diagrammatic overview of the Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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precise injection methodology utilized can be seen in Figure 4. 
As with previous studies, following injection the cords were 
ruptured 24 hours later via passive digital extension and the 
participants were asked to wear a night splint for 4 months. 
Three treatment cycles per DD cord were allowed. The pri-
mary end point remained extension to #5° within 30 days of 
the final injection alongside recording of all adverse reactions. 
The diseased joints were split into two baseline-characteristic 
matched groups, with 204 receiving CHC and 104 receiving 
placebo injections. The primary end point was achieved in 64% 
of the CHC group compared with 6.8% of joints in the placebo 
group. CHC-treated joints also showed a greater improvement in 
range of movement when compared with placebo-injected joints 
and all of the successfully treated joints showed no evidence 
of recurrence at the 90-day assessment. Of those CHC joints 
that did not achieve the primary end point, more than half did 
not receive the maximum allowable number (3) of CHC injec-
tions, either because the cord was no longer palpable (and thus 
could not safely be injected) or the patient was happy with the 
result despite lacking restoration of complete digital extension. 
However, preinjection baseline severity of contracture affected 
the likelihood of achieving the primary end point: 88.9% of 
CHC-injected MCPJ joints with a baseline contracture of 50° 
or less met the primary end point compared with 57.7% of 
those joints with a contracture greater than 50°; this effect was 
also seen in PIPJ joints (80.9% in the smaller than 40° group 
when compared with 22.4% in the greater than 40° group). This 
would suggest that CHC treatment may be more applicable 
for use in less severely affected joints, whereas perhaps those 
that are more severely contracted might derive greater benefit 
from traditional surgical correction. 96.6% of all CHC-treated 
joints developed one or more treatment-related adverse event as 
compared with 21.2% of those receiving the placebo injections; 
however, most were rated as mild to moderate with resolution 
without any medical intervention within a median of 10 days. 
Twenty-two patients (20   receiving CHC and two receiving 
placebo) reported adverse reactions, which they rated to be 
severe in nature, all of which were deemed to be treatment 
related except the single reports of contact dermatitis, muscular 
spasms, myocardial infarction (each in a CHC-treated patient), 
acute cholecystitis, nasopharyngitis, and radius fracture (each 
of which occurred in a placebo-group patient). The reported 
treatment-related events were primarily localized to the injection 
sites (edema [2%], pain [2%], hemorrhage [1.5%], contusion 
[1%], tenderness [1%], ecchymosis [0.5%], cellulitis [0.5%], 
and skin laceration [0.5%]) or to the injected side of the body 
(upper limb pain [2%] and chest-wall pain [0.5%]). Two par-
ticipants deemed their reaction to be too severe to continue with 
the CHC treatment: one due to local pain secondary to the first 
CHC injection and the other due to dizziness 28 days post-CHC 
treatment which the patient attributed to the treatment. However, 
the authors deemed that three participants who received CHC 
injections suffered serious adverse events directly related to 
the treatment: two cases of tendon rupture (requiring surgical 
reparation) and a case of complex regional pain syndrome. 
There were no clinically observed systemic allergic reactions, 
alterations in grip strength, nerve injuries, or deaths associated 
with the treatment. With regard to biochemical or immunologi-
cal response to the CHC, baseline blood results were compared 
with samples from 30 and 90 days posttreatment: $85.8% 
of those receiving a single injection developed anti-CHC 
antibodies, with 100% of patients testing positive following 
three injections. There were no clinically relevant blood result   
changes.
The final paper published to date, by Watt et al3 reviewed 
participants from an earlier study undertaken 8 years previ-
ously (published by Badalamente and Hurst and discussed 
previously). Twenty-three patients from a single study arm 
were contacted 8 years after their initial treatment. Of these 
23, only eight were alive, contactable at the same address, 
available within the study period and received a CHC injection 
and thus were eligible for reevaluation to assess the state of 
their DD since the study. Notably, seven of the eight subjects 
had a family history of DD making them more likely to have 
aggressive disease and be at higher risk of relapse. All patients 
had a single CHC injection, six into MCPJ and two into PIPJ; 
however, varying injection dosages were administered, and not 
all patients achieved the primary goal of extension to #5%. Of 
the MCPJ joints, two had no evidence of DD recurrence and 
four had recurrent disease, although the extent of contracture 
seen at the 8-year assessment was still less than that previously 
noted for pre-CHC injection in all four patients (60%–20%; 
70%–40%; 52%–20%; and 55%–55%, respectively). In the 
two PIPJ patients, there was a 100% recurrence rate with 
the degree of contracture (which initially demonstrated a 
marked improvement at the 1-year assessment) being more 
extensive than prior to the treatment (35% pretreatment, 0% 
at 1 year, and 50% at 8 years; and 55% pretreatment, 25% at 
1 year, and 70% at 8 years, respectively). Patients subjectively 
ranked the treatment as being 60% successful, and seven 
out of eight stated they would consider having the treatment   
again.
Discussion
DD is a prevalent disease that causes considerable impairment 
to patients’ hand function. It has a complex, multifactorial Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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etiology and pathophysiology, a complete understanding of 
which remains elusive. Despite explorative studies of a broad 
variety of alternative nonsurgical therapies, few of these 
have yet shown sufficient promise for them to be considered 
a valid alternative to the gold standard surgical methods 
that currently remain the mainstay of DD management. 
However, the developments discussed earlier in the use of 
CHC injection therapy indicate that this is likely to become 
a significant clinically applicable alternative method for the 
management of DD. Surgery is, however, likely to remain 
Indications & precautions
Post injection aftercare
MCP joint contractures
PIP joint contractures
Indicated in adults with palpable DD cord(s)
Use with caution and only if clearly indicated in pregnancy; no data available for use in breastfeeding women or
pediatric patients
Use with caution in patients with clotting disorders or in those who have taken anticoagulants (except low-dose
aspirin) in last 7 days
Use careful, joint-specific injection technique (as per below)
Post injection, wrap hand in bulky gauze dressing and elevate for the rest of the day •
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
24 hours post-injection, patient returns for passive digital extension to rupture cord – use moderate pressure for
10–20 seconds; if cord does not rupture, passive extension can be repeated up to 3 times at 5–10 minute intervals
If cord rupture is not achieved, the procedure may be repeated up to 3 times at 4 weekly intervals
Following cord rupture, patients should use a night splint and perform digital flexion/extension exercises 
several times per day for 4 months
Insert needle at point of maximum
bowstringing of palpable cord
0.25 mL sterile reconstituted CHC solution 3-point CHC
injection site
3-point CHC
injection site
NB skin to flexor tendon distance = average
7 mm
Vertical needle insertion
3-point distribution of each total injection
volume
Insert needle not more than 4 mm distal to
palmar digital crease to 2–3 mm depth
(NB bevel = 1.25 mm)
0.20 mL reconstituted CHC solution
NB skin to flexor tendon distance = average
4 mm
Needle insertion – horizontal to cord
3-point distribution of each total injection
volume
Figure 4 Diagram illustrating indications, relative contraindications, injection technique with adjustments for metacarpophalangeal (MCP) vs proximal interphalangeal (PiP) 
joints and suggested aftercare following successful Dupuytren disease (DD) cord rupture (as per Hurst et al5).
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a valid treatment option, especially for recurrent cases fol-
lowing CHC injection, in patients with the aggressive form 
of the disease (strong diathesis), and in those patients with 
PIPJ involvement (which appears to not respond as favorably 
to the CHC-based technique when compared with simple 
MCPJ disease). Figure 5 presents a treatment algorithm, 
illustrating where CHC injection is likely to contribute for 
the management of DD.
The CHC studies undertaken to date have clearly dem-
onstrated that injection of CHC is a valid alternative to 
the traditional surgical options, despite neither treatment 
facilitating a definitive cure. CHC demonstrates an impres-
sive degree of digital extension with low rates of disease 
recurrence – certainly the benefits it offers, such as reduced 
invasiveness and procedure time, rapidity of recovery of 
premorbid hand function and the likely reduction in cost of 
administration (being an office-based method rather than 
surgical theater-based technique) could be instrumental in its 
likely increase in popularity both with patients and surgeons 
over the coming years.
A precise comparison of procedure risk vs derived health 
benefit between the gold standard selective fasciectomy and 
CHC injection is difficult. Surgery, with its reported surgeon-
dependent and technique-dependent complication rate of 
17%–50%,24 still carries a significant morbidity. Some of the 
local complications are similar to those seen in CHC injection 
(local pain, tenderness, ecchymosis, edema, risk of infection, 
and hematoma are expected sequelae), but surgery is also 
associated, especially those more complex revision opera-
tions in which there is often considerable local scarring, with 
risk of flexor tendon or pulley injury, digital nerve damage, 
and reflex sympathetic dystrophy.87 CHC injection has also 
been noted to be associated with tendon rupture and complex 
regional pain syndrome (two of 204 and one of 204 patients, 
respectively, in Hurst et al’s most recent study5), but the 
authors suggested that the risk of these serious   complications 
might be minimized by careful adherence to the proposed 
injection technique, especially when injecting distal PIPJ 
contractures (see Figure 4). In view of this requirement for 
meticulous technique, it is clear that CHC injection will 
remain, based on the need for sound anatomical knowledge 
and manual dexterity, within the surgeons’ remit.
As with any novel therapy, the primary concerns that 
must be addressed prior to its use in the clinical environment 
are its efficacy – this has been illustrated in the previously 
mentioned studies – and whether the safety risks it imposes 
are outweighed by the health benefit it provides. As CHCs 
act via the degradation of collagen and 25%–33% of the total 
protein within humans is comprised of collagen,66 it is clear 
that it is essential to ensure CHCs act only on the diseased DD 
collagen against which they are therapeutically targeted.
The toxicity of intravenously injected CHC in mice was 
explored by Garvin Jr86 who showed a median lethal dose of 
1,176 ± 208 U/kg – the main signs of toxicity were pulmonary 
hemorrhage and disseminated tissue digestion. The authors 
extrapolated this to an average 70 kg human, suggesting a 
lethal dose of 89,040 U (although this is with direct intravenous 
administration which is likely to be substantially more systemi-
cally damaging when compared with contained local tissue 
injection). However, the manufacturers of Xiaflex® reported 
much higher estimated safety margins for the inadvertent 
intravenous administration of the drug, suggesting a minimum 
lethal dose of more than 43 times the recommended dosage. 
Rydevik et al88–91 undertook a number of studies into the effect 
of CHC on neural, vascular, epidural, and intrathecal tissues 
in animal models (rabbit ears and hamster cheek pouches). 
They demonstrated a dose-related short-term and long-term 
response within the microvasculature of rabbit ears to local 
CHC injection. At low doses (120 U/mL), acutely, there was 
a slight reduction in blood flow and functional recruitment 
of capillaries with a localized hyperemic area persisting at 
7 days postinjection and evidence of small vessel prolifera-
tion but not of revascularization. At high doses (3000 U/mL), 
an immediate transient hyperemia was seen, with stagnant 
flow in venules and capillaries at 60 minutes postinjection 
and evidence of microbleeding increasing over time. This 
progressed by day 3 to evidence of marked local hemorrhage 
extending beyond the injection site with a central area of 
necrosis observable – microangiograms displayed a central 
vessel-free zone with peripheral proliferation of wide, tortuous 
vessels typical of those seen in granulation tissue. In another 
study, they showed that CHC injected epidurally resulted in 
local dural thinning at higher concentrations, whereas even 
small concentrations of CHC injected intrathecally resulted 
in intrathecal hemorrhage and acute paraplegia. It might be 
assumed that such CHC-related neurological damage infers 
that a similar effect that might occur in digital nerves exposed 
to CHC, resulting in transient neuropraxia or persistent nerve 
damage. However, none of the clinical studies described in 
this review have noted any such clinical deficits. Perhaps this 
is due to the limited follow-up length and relatively small 
numbers treated to date or that, rather than directly damaging 
the neuronal fibers, the intrathecally injected CHC created 
a similar effect on the microvasculature as in the rabbit ear 
study, inducing a cord ischemia secondary to the local hype-
remia, hemorrhage, and resultant edema. Interestingly, at a Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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cellular level, Del Carlo et al17 noted no evidence of cell death 
or damage to nerve fibers at any of the CHC concentrations 
tested. Despite this lack of cellular sequelae, the manufac-
turers of the CHC Xiaflex® advise that CHC injection has 
not been tested in pregnant, breast-feeding, or pediatric 
populations in whom its safety and efficacy have not yet been   
established.
The ability to localize the effect of injected CHC has 
been demonstrated by Badalamente and Hurst92 who injected 
CHC in vivo into anesthetized rat tail tendons and dem-
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Focused DD history and
examination (exclude
differential diagnosis)
Observe & return if DD
becomes symptomatic or
starts progressing
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function?
Observe & return if hand
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Specialist
hand surgeon
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rapidly progressing?
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hand surgeon
Palpable cord? Extensive disease +/−
impalpable cord?
Consider CHC
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procedure as
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Figure 5 Flowchart for managing patients with Dupuytren disease (DD) from initial presentation to treatment, demonstrating the role of Clostridium histolyticum collagenase 
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onstrated that no adverse extravasation of CHCs (at doses 
between 150–300 U) occurred into adjacent muscle, nerve, 
other tendons, vessels, bone, or skin. Gelbard et al11 in their 
study investigating the effect of CHC in vivo, also used an 
anesthetized rat. CHC was injected into the left femoral 
adventitial tissues surrounding the femoral neurovascular 
bundle: histological examination revealed that the collag-
enolytic effect was limited purely to the injection site – only 
small local venules were degraded with sparing of the nerves 
and smooth muscle–containing arterioles. Indeed, Mandl93 
described the use of CHC to selectively remove connective 
tissue from the surrounding of nerves before histological 
studies of the intact nerves.
As CHC is a foreign protein, its injection would be presumed 
to evoke an immunological response. Indeed, Hamilton et al74 
demonstrated such an immune response to injection of CHC 
for the treatment of PD plaques: pretreatment, anticollagenase 
IgG was detected in 34% of the healthy controls vs 58% of 
untreated PD patients. Following intralesional CHC injection 
of 3,000–12,650 U, an increase of twofold to 10-fold in IgG 
levels was seen at 1–2 months postinjection in 88% of patients. 
Only 0.5% showed detectable collagenase-specific IgE antibody. 
Braun94 described a contact dermatitis in two patients in whom 
a topical ointment composed of CHC and chloramphenicol 
(Iruxol™; Smith & Nephew) was applied – although a positive 
local response was observed, no specific allergen was detected. 
Finally, Hurst et al5 demonstrated that $85.8% of those receiving 
a single in vivo CHC injection into DD-affected cords developed 
anti-CHC antibodies, with 100% of patients testing positive 
following three injections. However, they showed no clinical 
evidence of systemic allergic response.
With  respect  to  the  systemic  biochemical  and 
hematological response to local tissue injection of CHCs, 
Sussmann and Mann69,70,95,96 demonstrated no adverse changes 
in red blood cell, white blood cell, or platelet counts in rats 
receiving .100 times the effective dose required for interver-
tebral disc lysis. Hurst et al5 reported no clinically meaningful 
changes in hematological or biochemical variables following 
CHC injection in DD cords. Badalamente et al14 also reviewed 
the   pharmacokinetics of locally injected CHC, showing that 
despite no evidence of CHC circulating within serum, an 
estimated 28% of the dose injected was concentrated and 
excreted in the urine with no evidence of damage to the renal 
function. They suggested the absence of CHC within serum 
to be due to the CHC not being released into the circula-
tion as a bolus but rather via incremental leaching from the 
injection site – thus, the tiny volumes slowly released over 
the sampling period were below the 4 ng/mL test threshold. 
However, the manufacturers of Xiaflex® later repeated the 
pharmacokinetic studies and detected no systemic levels of 
CHC following a single-dose Xiaflex® injection. This lack 
of quantifiable systemic exposure negated the need for tissue 
distribution, metabolism, or excretion studies.99
Overall, it can be concluded that the efficacy, safety, and 
complication profiles of CHCs appear to compare favorably 
with the current surgical techniques in adult patients with a 
palpable DD cord. However, this is still a method relatively 
within its infancy and thus there is no evidence relating to the 
possible long-term sequelae of CHC injections, nor any indi-
cation as to its safety in pregnancy, in breast-feeding women 
or in pediatric patients – further studies will be required to 
elucidate any long-term issues with the technique.
Conclusion
DD is a prevalent disease that has a marked effect on 
patients’ hand function and for which there is still no cura-
tive treatment. CHC is a novel nonsurgical treatment option 
of considerable potential in the management of DD when 
administered by specialist hand surgeons with detailed 
knowledge of the disease and its relevant anatomy. CHC 
injection has been shown to have a good efficacy and safety 
profile when compared with the current gold standard of 
surgery and appears likely to have a role in the therapeutic 
arsenal for the management of DD.
Nonetheless, there is a need for further data on long-term 
results, complications, and rate of recurrence with the use of 
this emerging treatment option.
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